$GMED
GLOBUS MEDICAL INC

2012 Q4 Form 10-Q Financial Statement

#000123783112000031 Filed on November 02, 2012

View on sec.gov

Income Statement

Concept 2012 Q4 2012 Q3 2011 Q3
Revenue $100.5M $94.76M $84.27M
YoY Change 14.25% 12.45%
Cost Of Revenue $19.60M $18.87M $17.14M
YoY Change 0.51% 10.1%
Gross Profit $80.98M $75.89M $67.13M
YoY Change 18.21% 13.05%
Gross Profit Margin 80.55% 80.09% 79.66%
Selling, General & Admin $44.60M $41.78M $34.76M
YoY Change 17.68% 20.19%
% of Gross Profit 55.08% 55.05% 51.78%
Research & Development $7.200M $7.022M $5.916M
YoY Change 24.14% 18.7%
% of Gross Profit 8.89% 9.25% 8.81%
Depreciation & Amortization $4.600M $4.600M $4.300M
YoY Change -2.13% 6.98%
% of Gross Profit 5.68% 6.06% 6.41%
Operating Expenses $51.80M $48.83M $40.60M
YoY Change 18.81% 20.28%
Operating Profit $29.18M $27.06M $26.53M
YoY Change 17.16% 2.0%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 -$45.00K -$172.0K
YoY Change -100.0% -73.84%
Pretax Income $29.10M $27.02M $26.36M
YoY Change 23.83% 2.5%
Income Tax $8.300M $10.53M $9.494M
% Of Pretax Income 28.52% 38.97% 36.02%
Net Earnings $20.77M $16.49M $16.86M
YoY Change 53.04% -2.23%
Net Earnings / Revenue 20.66% 17.4% 20.01%
Basic Earnings Per Share $0.23 $0.18 $0.19
Diluted Earnings Per Share $0.22 $0.18 $0.19
COMMON SHARES
Basic Shares Outstanding 91.14M shares 90.11M shares 88.06M shares
Diluted Shares Outstanding 92.70M shares 90.40M shares

Balance Sheet

Concept 2012 Q4 2012 Q3 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $212.4M $195.2M
YoY Change 48.84%
Cash & Equivalents $212.4M $195.2M $127.3M
Short-Term Investments
Other Short-Term Assets $26.80M $23.00M
YoY Change 43.32%
Inventory $62.31M $57.04M
Prepaid Expenses
Receivables $53.50M $51.86M
Other Receivables $5.100M $6.300M
Total Short-Term Assets $360.1M $333.4M
YoY Change 39.16%
LONG-TERM ASSETS
Property, Plant & Equipment $61.09M $56.89M
YoY Change 16.6%
Goodwill $15.37M $15.34M
YoY Change 56.73%
Intangibles $9.585M $9.746M
YoY Change 28.95%
Long-Term Investments
YoY Change
Other Assets $977.0K $630.0K
YoY Change -0.31%
Total Long-Term Assets $87.02M $82.61M
YoY Change 23.24%
TOTAL ASSETS
Total Short-Term Assets $360.1M $333.4M
Total Long-Term Assets $87.02M $82.61M
Total Assets $447.1M $416.0M
YoY Change 35.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.991M $5.963M
YoY Change 87.69%
Accrued Expenses $25.00M $20.51M
YoY Change 17.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $39.51M $34.07M
YoY Change 34.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.500M $3.185M
YoY Change 25.04%
Total Long-Term Liabilities $3.500M $3.185M
YoY Change 25.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $39.51M $34.07M
Total Long-Term Liabilities $3.500M $3.185M
Total Liabilities $60.63M $51.78M
YoY Change 29.24%
SHAREHOLDERS EQUITY
Retained Earnings $250.7M $229.9M
YoY Change 41.75%
Common Stock $91.00K $91.00K
YoY Change 24.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $386.5M $364.3M
YoY Change
Total Liabilities & Shareholders Equity $447.1M $416.0M
YoY Change 35.75%

Cashflow Statement

Concept 2012 Q4 2012 Q3 2011 Q3
OPERATING ACTIVITIES
Net Income $20.77M $16.49M $16.86M
YoY Change 53.04% -2.23%
Depreciation, Depletion And Amortization $4.600M $4.600M $4.300M
YoY Change -2.13% 6.98%
Cash From Operating Activities $24.70M $16.90M $23.40M
YoY Change 9.29% -27.78%
INVESTING ACTIVITIES
Capital Expenditures -$7.700M -$5.200M -$3.700M
YoY Change 13.24% 40.54%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$6.000M $0.00
YoY Change
Cash From Investing Activities -$7.600M -$11.30M -$3.700M
YoY Change 11.76% 205.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 100.0K 24.00M 200.0K
YoY Change 11900.0%
NET CHANGE
Cash From Operating Activities 24.70M 16.90M 23.40M
Cash From Investing Activities -7.600M -11.30M -3.700M
Cash From Financing Activities 100.0K 24.00M 200.0K
Net Change In Cash 17.20M 29.60M 19.90M
YoY Change 8.86% 48.74%
FREE CASH FLOW
Cash From Operating Activities $24.70M $16.90M $23.40M
Capital Expenditures -$7.700M -$5.200M -$3.700M
Free Cash Flow $32.40M $22.10M $27.10M
YoY Change 10.2% -18.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5963000 USD
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5323000 USD
CY2012Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
4837000 USD
CY2011Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
1178000 USD
CY2011Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
1200000 USD
CY2012Q3 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
4800000 USD
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
46727000 USD
CY2012Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
51863000 USD
CY2012Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1389000 USD
CY2011Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
302000 USD
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21268000 USD
CY2012Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20510000 USD
CY2012Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1659000 USD
CY2011Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1497000 USD
CY2012Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-815000 USD
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1202000 USD
CY2012Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
135076000 USD
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
106708000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3682000 USD
us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
2644000 USD
CY2011Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
765000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3682000 USD
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1545000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2151000 USD
CY2012Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
931000 USD
CY2011Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
602000 USD
CY2011Q4 us-gaap Assets
Assets
329390000 USD
CY2012Q3 us-gaap Assets
Assets
416042000 USD
CY2011Q4 us-gaap Assets Current
AssetsCurrent
258775000 USD
CY2012Q3 us-gaap Assets Current
AssetsCurrent
333432000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142668000 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
195156000 USD
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
127329000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111701000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
52488000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
15628000 USD
CY2012Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
679178000 shares
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
785000000 shares
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72528569 shares
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91127063 shares
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91127063 shares
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72528569 shares
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
73000 USD
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
91000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
53451000 USD
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
16800000 USD
CY2011Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
16411000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
46780000 USD
CY2012Q3 us-gaap Goodwill
Goodwill
15342000 USD
CY2011Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
17141000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
49309000 USD
CY2012Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
18872000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
55642000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-5057000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
190000 USD
CY2011Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
16160000 USD
CY2012Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
19849000 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
5755000 USD
CY2012Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
4395000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12202000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13500000 USD
CY2011Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.54
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.58
CY2011Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.19
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-83000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-282000 USD
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.357
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.380
CY2012Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13861000 USD
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13145000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
-2644000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
54000 USD
CY2012Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
408000 USD
CY2011Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
70000 USD
CY2012Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-30000 USD
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-306000 USD
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
801000 USD
CY2011Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
78000 USD
CY2011Q4 us-gaap Goodwill
Goodwill
9808000 USD
CY2011Q3 us-gaap Gross Profit
GrossProfit
67129000 USD
us-gaap Gross Profit
GrossProfit
194176000 USD
CY2012Q3 us-gaap Gross Profit
GrossProfit
75892000 USD
us-gaap Gross Profit
GrossProfit
229816000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
73457000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
85559000 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
27015000 USD
CY2011Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
26357000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26243000 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10528000 USD
CY2011Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9494000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32495000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
25688000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
36317000 USD
CY2012Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
6346000 USD
CY2011Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
3336000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4187000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
34000 USD
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
3659000 USD
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
1115000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5277000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
868000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
3362000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
2539000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1618000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-730000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
11044000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
14587000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1117000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
326000 USD
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2663000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2590000 shares
CY2012Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2586000 shares
CY2011Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2335000 shares
CY2012Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9746000 USD
CY2011Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7433000 USD
us-gaap Interest Paid
InterestPaid
275000 USD
us-gaap Interest Paid
InterestPaid
39000 USD
CY2012Q3 us-gaap Inventory Net
InventoryNet
57038000 USD
CY2011Q4 us-gaap Inventory Net
InventoryNet
47369000 USD
us-gaap Inventory Write Down
InventoryWriteDown
5386000 USD
us-gaap Inventory Write Down
InventoryWriteDown
6793000 USD
CY2011Q4 us-gaap Liabilities
Liabilities
46914000 USD
CY2012Q3 us-gaap Liabilities
Liabilities
51780000 USD
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
416042000 USD
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
329390000 USD
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
34074000 USD
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29271000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14654000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18565000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23063000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23194000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
57069000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
53758000 USD
us-gaap Net Income Loss
NetIncomeLoss
53064000 USD
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
16863000 USD
us-gaap Net Income Loss
NetIncomeLoss
47214000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
16487000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
47214000 USD
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
16487000 USD
CY2011Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
16863000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
53064000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Operating Expenses
OperatingExpenses
144133000 USD
us-gaap Operating Expenses
OperatingExpenses
120526000 USD
CY2011Q3 us-gaap Operating Expenses
OperatingExpenses
40600000 USD
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
48832000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
85683000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
27060000 USD
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
26529000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
73650000 USD
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3850000 USD
CY2012Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3311000 USD
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
980000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-434000 USD
CY2011Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-452000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
387000 USD
CY2011Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-452000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-434000 USD
CY2012Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
630000 USD
CY2012Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
313000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
387000 USD
CY2012Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
313000 USD
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2799000 USD
CY2012Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3185000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-124000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-193000 USD
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-45000 USD
CY2011Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-172000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
10000000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
6031000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
7500000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15694000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17032000 USD
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50691000 shares
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50691000 shares
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
50691000 shares
CY2012Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
50691000 shares
CY2012Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
51000 USD
CY2012Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3180000 USD
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2515000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
25000000 USD
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56892000 USD
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52394000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
93000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
336000 USD
us-gaap Related Party Transaction Purchases From Related Party
RelatedPartyTransactionPurchasesFromRelatedParty
13498000 USD
CY2012Q3 us-gaap Related Party Transaction Purchases From Related Party
RelatedPartyTransactionPurchasesFromRelatedParty
6894000 USD
CY2011Q3 us-gaap Related Party Transaction Purchases From Related Party
RelatedPartyTransactionPurchasesFromRelatedParty
4587000 USD
us-gaap Related Party Transaction Purchases From Related Party
RelatedPartyTransactionPurchasesFromRelatedParty
15418000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5253000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5916000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17691000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20698000 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7022000 USD
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
229910000 USD
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
176846000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
285458000 USD
CY2012Q3 us-gaap Sales Revenue Net
SalesRevenueNet
94764000 USD
CY2011Q3 us-gaap Sales Revenue Net
SalesRevenueNet
84270000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
243485000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
102529000 USD
CY2011Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34762000 USD
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
41780000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
124236000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2151000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3682000 USD
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3161917 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4264000 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
636000 USD
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
192000 USD
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
8684000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11070000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
256000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1169000 shares
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
204615 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.30
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.57
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.01
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
71789000 USD
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6454000 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6449000 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.90
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.14
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.14
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.15
CY2011Q4 gmed Business Acquisition Liabilities Noncurrent
BusinessAcquisitionLiabilitiesNoncurrent
9089000 USD
CY2012Q3 gmed Business Acquisition Liabilities Noncurrent
BusinessAcquisitionLiabilitiesNoncurrent
10126000 USD
CY2012Q3 gmed Intangible Assets Gross
IntangibleAssetsGross
10154000 USD
CY2011Q4 gmed Intangible Assets Gross
IntangibleAssetsGross
7503000 USD
gmed Number Of Product Categories
NumberOfProductCategories
2
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.00
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
58150000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M24D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
918000 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20963000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1046000 USD
CY2011 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
1233397 shares
CY2012Q3 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
282476000 USD
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
364262000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-113000 USD
us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
-900000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Significant areas that require management&#8217;s estimates include intangible assets, contingent payment liabilities, allowance for doubtful accounts, stock-based compensation, provision for excess and obsolete inventory, useful lives of assets, the outcome of litigation, and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results. </font></div></div>
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92697000 shares
CY2011Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90398000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90709000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91563000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88900000 shares
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90111000 shares
CY2011Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88063000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88119000 shares
CY2011Q4 gmed Accrued Liabilities Legal And Other Settlements And Expenses
AccruedLiabilitiesLegalAndOtherSettlementsAndExpenses
2776000 USD
CY2012Q3 gmed Accrued Liabilities Legal And Other Settlements And Expenses
AccruedLiabilitiesLegalAndOtherSettlementsAndExpenses
1679000 USD
CY2012Q3 gmed Business Acquisition Liabilities Current
BusinessAcquisitionLiabilitiesCurrent
1375000 USD
CY2011Q4 gmed Business Acquisition Liabilities Current
BusinessAcquisitionLiabilitiesCurrent
1200000 USD
gmed Payment Of Business Acquisition Liabilities
PaymentOfBusinessAcquisitionLiabilities
800000 USD
gmed Payment Of Business Acquisition Liabilities
PaymentOfBusinessAcquisitionLiabilities
0 USD
gmed Proceeds From Issuance Initial Public Offering Net Of Underwriting Fees And Offering Expenses
ProceedsFromIssuanceInitialPublicOfferingNetOfUnderwritingFeesAndOfferingExpenses
0 USD
gmed Proceeds From Issuance Initial Public Offering Net Of Underwriting Fees And Offering Expenses
ProceedsFromIssuanceInitialPublicOfferingNetOfUnderwritingFeesAndOfferingExpenses
20963000 USD
gmed Proceeds From Issuance Of Common And Preferred Stock
ProceedsFromIssuanceOfCommonAndPreferredStock
1046000 USD
gmed Proceeds From Issuance Of Common And Preferred Stock
ProceedsFromIssuanceOfCommonAndPreferredStock
545000 USD
CY2012Q3 gmed Reverse Stock Split Conversion Ratio
ReverseStockSplitConversionRatio
3.25
CY2012Q3 gmed Share Based Compensation Arrangement By Share Based Payment Award Options Grants Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsExercisePrice
12.00
CY2012Q2 gmed Share Based Compensation Arrangement By Share Based Payment Award Options Grants Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsExercisePrice
12.00
CY2012Q3 gmed Share Based Compensation Number Of Stock Plans
ShareBasedCompensationNumberOfStockPlans
3
gmed Unrealized Gain Loss On Contingent Consideration
UnrealizedGainLossOnContingentConsideration
-23000 USD
gmed Unrealized Gain Loss On Contingent Consideration
UnrealizedGainLossOnContingentConsideration
-182000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001237831
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
91136285 shares
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
GLOBUS MEDICAL INC

Files In Submission

Name View Source Status
0001237831-12-000031-index-headers.html Edgar Link pending
0001237831-12-000031-index.html Edgar Link pending
0001237831-12-000031.txt Edgar Link pending
0001237831-12-000031-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
gmed-20120930.xml Edgar Link completed
gmed-20120930.xsd Edgar Link pending
gmed-20120930_cal.xml Edgar Link unprocessable
gmed-20120930_def.xml Edgar Link unprocessable
gmed-20120930_lab.xml Edgar Link unprocessable
gmed-20120930_pre.xml Edgar Link unprocessable
gmed93012ex311.htm Edgar Link pending
gmed93012ex312.htm Edgar Link pending
gmed93012ex32.htm Edgar Link pending
gmed_9301210q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending